Available Genomic Tests for Clinically Localized Prostate Cancer

A review of the currently available genomic testing options for patients with clinically localized prostate cancer and the NCCN and AUA/ASTRO recommendations based on risk group.

EP: 1.Staging, Grading, and Risk Stratification of Prostate Cancer

EP: 2.Treatment Options for High-Risk, Clinically Localized Prostate Cancer

EP: 3.Clinical Challenges Surrounding Treatment Decision-Making in Clinically Localized Prostate Cancer

EP: 4.The Potential for Overtreatment or Undertreatment of Prostate Cancer

EP: 5.Addressing Clinical Challenges of Prostate Cancer Management with the Use of Genomic Testing

Now Viewing

EP: 6.Available Genomic Tests for Clinically Localized Prostate Cancer

EP: 7.Clinical Study Data in Prostate Cancer Genomic Testing

EP: 8.Clinical Implications of Using Genomic Testing Results in Prostate Cancer Risk-Stratification and Treatment Selection

EP: 9.Exciting Emerging Data in Prostate Cancer

Related Videos

Related Content

Advertisement

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

July 9th 2025

FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

Benjamin P. Saylor Hannah Clarke

The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

July 7th 2025

Expanded indication sought for niraparib plus AAP in Europe

Hannah Clarke

The application is supported by data from the phase 3 AMPLITUDE trial.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.

Related Content

Advertisement

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

July 9th 2025

FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

Benjamin P. Saylor Hannah Clarke

The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

July 7th 2025

Expanded indication sought for niraparib plus AAP in Europe

Hannah Clarke

The application is supported by data from the phase 3 AMPLITUDE trial.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.